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According to the European Society of Cardiol-
ogy guidelines dual antiplatelet therapy (DAPT) for 
12 months, angiotensin-converting enzyme inhibitor 
(ACEI) or angiotensin receptor blocker (ARB), be-
ta-blocker and statin [1] are recommended in patients 
after myocardial infarction (MI). Adherence to this 
treatment determines the achievement of therapeutic 
targets [2–8]. Previous studies have shown that patients 
after MI often do not adhere to the treatment plan. 
Discontinuation of the recommended post-MI therapy 
predisposes to serious thrombotic events, particularly 
MI, in-stent thrombosis, stroke and death [9–14]. The 
knowledge regarding the level and determinants of 
adherence to treatment recommendations in post-MI 
patients enables proper care and education planning 
for this population. 
The series of recent publications reporting results of 
a single centre, observational, cohort clinical trial with 
1-year follow-up, was intended to reflect ‘real world’ 
practice [15–18]. All study participants received in-hos-
pital educational and motivational verbal interventions 
on ischemic heart disease, focusing on its symptoms 
and management supported by an educational bro-
chure entitled “Myocardial infarction” that was handed 
out at the beginning of hospitalization. The first edu-
cational visit was carried out within the first two days 
after admission to the hospital. The visit included an 
assessment of patient knowledge of the disease, its 
symptoms, and prevention (20 standardized questions). 
Throughout the entire hospital stay, patients had an 
opportunity to ask questions and obtain comprehensive 
answers. The educational and motivational visits were 
conducted by trained educational nurses. 
The readiness for discharge from the hospital was 
assessed using a validated questionnaire Readiness 
for Hospital Discharge after Myocardial Infarction Scale 
(RHD-MIS) [19, 20]. The RHDS-MIS consists of 23 ques-
tions included in three subscales assessing subjective 
(assessed by the patient) and objective (assessed by 
medical personnel) knowledge about the disease and 
patient expectations. Additionally, the questionnaire 
contains non-scored questions regarding the patient’s 
opinion on the readiness for discharge. 
The analysis of medication discontinuation was 
performed based on prescription filling data provided by 
the National Health Fund (NHF) for reimbursed drugs: 
ACEI (ramipril, perindopril) P2Y12 receptor inhibitor 
(clopidogrel) and statin (atorvastatin, simvastatin, rosu-
vastatin). The NHF is the only institution in Poland that 
covers the costs of hospitalization, outpatient treatment 
and prescribed medications. Drugs non-reimbursed 
by the NHF were not included in the analysis. All study 
participants patients received appropriate prescrip-
tions (including ACEI, P2Y12 receptor inhibitor and 
statin) at discharge from the hospital. Two hundred 
fifty-two patients were enrolled on the study. The final 
analysis was conducted for 225 participants (73.3% 
men, 26.7% women) aged 30–91 years (mean age 
62.9 ± 11.9 years), for whom data were obtained from 
the National Health Fund. 
According to the authors’ best knowledge, this 
research [15–18] is the first one to comprehensively 
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analyse the level of adherence to medication and its 
determinants as well as the variability of these deter-
minants during the follow-up after hospital discharge. 
The mean adherence level during 1-year of follow-up 
for all three groups of medications (ACEIs, P2Y12 recep-
tor inhibitors and statins) was 64.1 ± 24.5%, with a value 
of 67.2 ± 31.8% for ACEI, 61.6 ± 34.2% for P2Y12 re-
ceptor inhibitors, and 64.4 ± 32.1% for statins. Over 
time, a gradual decline in adherence was observed for 
all groups of medications. Sufficient adherence for all 
medication groups was found only in 29.4% of patients 
throughout the whole follow-up period [15–18]. These 
findings are in line with those obtained by Naderi et al. 
[2] in a meta-analysis of 20 studies evaluating 7 groups 
of drugs showing a mean adherence level of 57.0% and 
its decline over consecutive quarters of follow-up. Similar 
findings were reported also in other publications [11–14].
The multivariate analysis defined determinants of 
medication adherence: age under 65 years in the first 
quarter of follow-up for ACEI, P2Y12 receptor inhibitor 
and statin; prior CABG in the 1st quarter of follow up for 
ACEI and P2Y12 receptor inhibitor; level of education 
and place of residence for P2Y12 receptor inhibitor in 
the 1st quarter of follow-up; economic status for all as-
sessed drugs in the 2nd quarter; marital status for ACEI 
in the 1st quarter of follow-up; arterial hypertension for 
ACEI in the 1st quarter of follow-up [15–18]. Identifying 
the factors responsible for the decline in adherence in 
the sequential quarters helps better understand the 
mechanisms governing this phenomenon and apply 
targeted corrective interventions. Additional educational 
and motivational efforts should be directed to elderly, 
less educated, living alone patients and those after 
CABG in order to increase the likelihood of implemen-
tation of prescribed medication after discharge from the 
hospital. Maintenance of medication during long term 
treatment requires special support in rural residents and 
patients with lower economic status [15–18]. 
The therapy discontinuation remains a challenge 
for therapeutic teams. Elimination of this phenomenon 
might largely improve the clinical and economical out-
comes of treatment [3, 8, 16]. 
The highest likelihood of therapy discontinuation, 
including long-term discontinuation (> 30 days) and 
permanent therapy cessation was found for statins and 
the lowest for ACEIs. It was found that patients are most 
prone to discontinue therapy between the 2nd and 3rd 
quarter of follow-up. In contrast to the permanent ces-
sation of therapy, a significant increase in the incidence 
of temporary therapy discontinuation was already seen 
in the 1st quarter of follow-up [15–18]. 
Multivariate logistic regression analysis identified 
occupational activity and a prior MI as independent 
predictors of lack of post-discharge therapy initiation 
with P2Y12 receptor inhibitors. The research found no 
predictors of lack of post-discharge therapy initiation 
with other medications either when analysed individually 
or together. Multivariate analysis indicated age above 
65 years and prior revascularization as independent 
predictors of therapy discontinuation but failed to iden-
tify independent predictors of the permanent cessation 
of therapy with any of the medications as well as the 
temporary discontinuation and permanent cessation of 
treatment with all three medications together [15–18]. 
Preparation for discharge, including education in 
the field of secondary prevention after a MI, is a current 
standard of care, however, not always meeting the 
patient’s expectations [21–27]. 
The assessment of readiness for discharge was based 
on the RHD-MIS. The analysis of adherence to treatment 
in relation to the results achieved in RHD MIS did not 
provide unequivocal results both in terms of the overall 
result and the results in individual subscales. This applies 
to individual drug groups tested separately and to all 
groups together. Significant differences noted in individual 
quarters for individual drugs may, contrary to expectations, 
suggest worse adherence in patients who were better 
prepared for discharge from the hospital [15–18]. These 
surprising results require further in-depth research to 
explain this phenomenon. According to the previously 
published studies, better adherence to treatment should 
be expected in patients with a higher level of readiness 
for discharge. The study confirms that patient education 
should continue after discharge from the hospital [26–36]. 
The patients with a high expectation score had lon-
ger treatment interruptions only for the P2Y12 receptor 
inhibitor. No relations between medication adherence 
and the level of expectations were found in the first two 
quarters, while for the last two-quarters of follow-up, 
however, an inverse relationship between the level of 
expectations and adherence was shown. When related 
to the levels of expectations (high vs medium vs low), 
adherence for ACEI in the 4th quarter of follow-up was 
39 ± 31% vs. 58 ± 43% vs. 57 ± 43% (p = 0.0099; 
R = -0,16; p = 0.0187). Similarly, for P2Y12 inhibitor the 
numbers were 37 ± 41% vs. 53 ± 43% vs. 55 ± 41% 
(p = 0.0282; R = -0,15; p = 0.0438). No differences, 
however, were found for statins [15–18]. 
The observed relation of expectations and adher-
ence might indicate a mismatch between the educa-
tional contents and patient expectations. The study 
protocol, however, did not include additional education-
al initiatives to be delivered to fulfil patient individual ex-
pectations after the provision of the standard education 
intervention.  The identification of patient expectations 
might allow further personalization of educational and 
motivational programmes [15–18]. 
Several limitations of the research reported in the 
series of publications should be considered. Medi-
cations non-reimbursed by the National Health Fund 
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were excluded from the analysis. The authors analysed 
a limited number of factors as potential determinants 
of therapy discontinuation. Moreover, the authors do 
not have patients’ reports concerning the reasons 
for therapy discontinuation. On the other hand, the 
strengths of this research are comprehensiveness and 
the homogeneity of the study population. 
The reported research enabled making several 
important observations. 
The vast majority of post-MI patients discontinue, 
either temporarily or permanently, one of the essential 
medications within one year following MI. Adherence to 
pharmacotherapy decreases over time after MI. Several 
socioeconomic and clinical factors have been identified 
to affect medication adherence over time. The readiness 
for discharge from the hospital assessed with the RHD-
MIS does not clearly affect the implementation of the 
therapeutic plan in the long-term follow-up in patients 
after MI. Data suggesting a negative impact of some 
aspects of readiness for discharge on adherence to 
treatment require further, in-depth research. 
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